LAS VEGAS, November 8, 2017 /PRNewswire/ --
The 2016 electionscreated a lot of excitement among marijuana and CBD supporters, as voters approved marijuana legalization in eight states, including four states (California, Maine, Massachusetts,
This has policy-makers thinking more approvals could be coming that further expand the legal marijuana market. As such, investors are increasingly looking for stocks that could benefit from growing marijuana use, while there are some obvious routes like drug companies seeking to profit from developing marijuana-derived medicines. There are also companies utilizing the medicinal properties of CBD to improve non medicinal products.
A few Marijuana/CBD companies we're tracking include: NightFood Holdings (OTC: NGTF), GW Pharmaceuticals Plc (NASDAQ: GWPH), Insys Therapeutics (NASDAQ: INSY), Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP), and AbbVie Inc. (NYSE: ABBV). NightFood Holdings (OTC: NGTF)
Market Cap: $2.7 Million Share Price: $0.089
NGTF announced it is working on making snacks utilizing CBD which has been found to promote and support better sleep. NightFood is already is the first (and currently only) nutrition company to formulate and manufacture sleep friendly snacks to solve the $50 Billion dollar nighttime craving problem. Their first product is the NightFood nutrition bar which is selling on Amazon. The product is highly rated and has been gaining traction since becoming available toward the middle of June. The company is also planning additional snack formats, including the late night snacking staple: ice cream. CBD snacks would be a huge benefit for this already exciting company.
GW Pharmaceuticals Plc (NASDAQ: GWPH)
Market Cap: $2.88 Billion Share Price: $113.84
GWPH has one of the most robust pipeline of potential marijuana medicines. The company has already won European approval for its THC drug, Sativex, for treating multiple sclerosis-related muscle spasms, and it's researching therapies created from the marijuana cannabinoid CBD, too.
Insys Therapeutics (NASDAQ: INSY)
Market Cap: $375.74 Million Share Price: $376.84
INSY had a ferociously frightening month, highlighted by the arrest of its founder, the setting aside of $150 million for lawsuits, and slumping sales. All this was behind a 42% crash in October, according to S&P Global Market Intelligence . Insys Therapeutics' troubles stem from Subsys, a powerful fentanyl spray approved to treat breakthrough pain in cancer patients.
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP)
Market Cap: $381.37 Million Share Price: $6.93
CRBP has seen some dramatic ups and downs over the past year. Hopes rise and fall for its marijuana-based drugs, which are in clinical trials. Resunab, which is designed to treat sclerosis, has had promising trials. The stock has tended to dip just before trial results are announced and then rally when the results are positive. Corbus is now testing Resunab as a treatment for cystic fibrosis. The pessimism/optimism pattern will likely continue to play out as this drug is tested yet again. The company has negative operating income, and revenues are close to zero. Corbus is a company depending on the success of a single drug that could make or break it.
AbbVie Inc. (NYSE: ABBV)
Market Cap: $148.2 Billion Share Price: $92.97
ABBV is a pharmaceutical company that is ahead of the pack because it has a cannabis-based drug on the market. The FDA approved Marinol, which helps alleviate nausea or vomiting for chemotherapy patients. The drug also helps AIDS patients who have lost their desire to eat. It is important to note that Marinol is not AbbVie's flagship drug. In fact, it is not even the company's biggest seller. The company is benefiting from a host of useful drugs, including Marinol. AbbVie is another way to play the marijuana trend without incurring 100% exposure to the plant much like NightFood Holdings (NGTF).
Content Provided By: Microcap Speculators
For Full Legal Disclaimer Click Here.
DISCLAIMER: Microcapspeculators.com (MS) is the source of the content set forth above. References to any issuer other than the profiled issuer are intended solely to identify industry participants and do not constitute an endorsement of any issuer and do not constitute a comparison to the profiled issuer. FN Media Group (FNM) is a third-party publisher and news dissemination service provider, which disseminates electronic information through multiple online media channels. FNM is NOT affiliated with MS or any company mentioned herein. The commentary, views and opinions expressed in this release by MS are solely those of MS and are not shared by and do not reflect in any manner the views or opinions of FNM. Readers of this Article and content agree that they cannot and will not seek to hold liable MS and FNM for any investment decisions by their readers or subscribers. MS and FNM and their respective affiliated companies are a news dissemination and financial marketing solutions provider and are NOT registered broker-dealers/analysts/investment advisers, hold no investment licenses and may NOT sell, offer to sell or offer to buy any security.
MS Disclosure: Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. ACR Communication, LLC. which owns Microcapspeculators.com, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. ACR Communication, LLC. which owns, Microcapspeculators.com may from time to time have a position in the securities mentioned herein and may increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice. ACR Communication LLC. which owns Microcapspeculators.com may be compensated for its services in the form of cash-based compensation or in equity in the companies it writes about, or a combination of the two.
This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company's annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and MS and FNM undertake no obligation to update such statements.
Media Contact FN Media Group LLC e-mail: firstname.lastname@example.org +1-(954)-345-0611
Subscribe to our Free Newsletters!
Drug hypersensitivity is an adverse reaction that occurs due to an interaction between a drug and ...
Stiff joints are a major problem for the elderly, as the joints tend to wear-and-tear with ...
Uterine/Endometrial cancer is the sixth most common cancer in women worldwide. Uterine cancer ...View All